Icecure Medical Ltd (ICCM) FinancialsICCMIcecure Medical Ltd

Evaluating the bottom line, Icecure Medical Ltd maintains a gross margin of 27.89%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -487.76%, while the net margin is -496.25%. These profitability ratios, combined with a Return on Equity (ROE) of -228.31%, provide a clear picture of how effectively ICCM converts its operational activities into shareholder value.

In the context of the broader market, ICCM competes directly with industry leaders such as CELZ and NDRA. With a market capitalization of $10.35M, it holds a leading position in the sector. When comparing efficiency, ICCM's gross margin of 27.89% stands against CELZ's N/A and NDRA's N/A. Such benchmarking helps identify whether Icecure Medical Ltd is trading at a premium or discount relative to its financial performance.

Icecure Medical has shown a significant revenue increase of 45% year-over-year for H1 2026, reaching $1.8 million, but continues to report substantial net losses, with a net loss of $8.8 million in the same period. The gross margin has improved slightly to 30%, indicating some operational leverage, but overall profitability remains elusive.